Skip to main content

Table 1 Demographic characteristics of patients eligible for anti-TNF therapy

From: Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study

Variable Value
Patients, n 77
Male/female, n 42/35
Average age, years, n (SD) 55.3 (12.5)
Rheumatoid arthritis patients, n (%) 36 (46.8)
Psoriatic arthritis patients, n (%) 24 (31.2)
Ankylosing spondylitis patients, n (%) 17 (22.1)
DMARDs intake, n (%) 55 (71.4)
Methotrexate, n (%) 31 (56.4)
Cyclosporin, n (%) 10 (18.0)
Leflunomide, n (%) 4 (7.0)
Steroids intake, n (%) 12 (15.6)
Anti-TNF intake, n (%) 75 (97.4)
Infliximab, n (%) 38 (51.0)
Adalimumab, n (%) 19 (25.0)
Etanercept, n (%) 18 (24.0)
Antinuclear antibodies positivity, n (%)* 10 (13.0)
Rheumatic factor positivity, n (%)* 28 (36.4)
Anti-citrullinated antibodies positivity, n (%)* 29 (37.7)
  1. *Refers to the total number of the patients in this study.